C Diff Drug Development

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB...

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, announced that it will be discontinuing its work with the U.S. Department of Defense (DoD) under a prototype research and development agreement. The agreement, which was awarded in the summer of 2019, unde

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel...

Immunoinformatics allows researchers to develop vaccines without microbial culturing, thus saving time and money.

Background: Clostridium difficile infection (CDI) has been widely reported in human and animals around the world over the past few decades. The high relapse rate and increasing drug resistance of CDI make the discovery of new agents against C. difficile fairly urgent. This study …

Kefir, a fermented beverage made from kefir grains, has gained immense popularity around the world due to its potential health-promoting properties. Kefir beverages are both marketed commerciall...

Scientists have created a probiotic to restore bile salt metabolism found in the gastrointestinal tract, to counter the onset and effects of Clostridium Difficile Infection (CDI).

Clostridioides difficile infection is a global health threat and remains the primary cause of hospital-acquired infections worldwide. The burgeoning incidence and severity of infections coupled with high rates of recurrence have created an urgent need for novel therapeutics. Here, we report a novel …

Summary clinical trial report, “Clostridioides difficile Infections (Clostridium difficile Associated Disease) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update" provides an overview of Clostridioides difficile Infections (Clostridium difficile Associated Disease) Clinical trials scenario.New York, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Clostridioides difficile Infe

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

Seres Therapeutics (MCRB) is trading 16% higher after the company on Wednesday said it expects to complete SER-109, its experimental oral microbiome therapeutic to reduce C

By Connor Hart Seres Therapeutics Inc. shares were almost 10% higher Wednesday afternoon after positive research results but below-expected earnings. The...

[SER-109: oral microbiome therapy for recurrent Clostridioides difficile infections : SER-109 versus Placebo in the Treatment of Adults with Recurrent Clostridium Difficile Infection (ECOSPOR III)]

Recently, a worrying acceleration of the emergence of antibiotic-resistant bacteria has been reported. The increase in antibiotic-associated diseases, such as Clostridioides difficile infection (CDI), has promoted research on new treatments that could be more effective and less aggressive for …

Dr Feuerstadt discusses data with 4 emerging microbiota-based live biotherapeutics for treatment of rCDI: RBX2660, SER-109, CP101, and VE303.

By Joe Hoppe Destiny Pharma PLC said Tuesday that a study of its Clostridioides difficile preventative treatment showed positive results. The London-listed...

The biotech is making final preparations to take NTCD-M3, a new antibiotic treatment for CDI, into phase III clinical trials

New study data for Destiny Pharma's NTCD-M3 offers further validation of its potential to prevent C. difficile infection recurrence as it progresses towards Phase 3 clinical trials.

Charlton Athletic owner Thomas Sandgaard has confirmed negotiations are ongoing to sign Crystal Palace attacker Jesurun Rak-Sakyi on loan.

The microbiota-based live therapeutic had a 68.3% success rate when administered following antibiotic treatment, versus a 55% success rate in a placebo group.

Clostridioides difficile (Cdiff) infection (CDI) continues to be the leading threat of nosocomial deaths worldwide and a major burden on health-care systems. Broad-spectrum antibiotics eradicate the normal gut microbiome, killing protective commensal bacteria and increasing CDI recurre …

C. difficile infection (CDI) is a highly inflammatory disease mediated by the production of two large toxins that weaken the intestinal epithelium and cause extensive colonic tissue damage. Antibiotic alternative therapies for CDI are urgently needed as current antibiotic regimens prolong the pertur …

Reduction of Clostridioides difficile infection (CDI) recurrence is an essential endpoint for CDI-directed antibiotic development that is often not evaluated until Phase III trials. The purpose of this project was to use a functional and metagenomic approach to predict the potential anti-CDI recurre …

Probiotics are live microorganisms that, when administered in adequate amounts, provide health benefits to the host. Some strains of the probiotic Lactobacillus reuteri (L. reuteri) have both antimicrobial and anti-inflammatory properties that may be exploited for the treatment and pre …

Menlo Park, CA, July 14, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today provided an update...

Long-term treatment of functional dyspepsia with proton-pump inhibitors can alter the gut microbiome. A new pilot randomized, double-blind, placebo-controlled trial suggests the potential of spore-forming probiotics in patients with functional dyspepsia.